{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T21:23:45Z","timestamp":1792704225690,"version":"4.5.0"},"reference-count":42,"publisher":"Impact Journals, LLC","issue":"32","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Oncotarget"],"published-print":{"date-parts":[[2015,10,20]]},"DOI":"10.18632\/oncotarget.5582","type":"journal-article","created":{"date-parts":[[2015,9,29]],"date-time":"2015-09-29T21:54:23Z","timestamp":1443563663000},"page":"33961-33971","source":"Crossref","is-referenced-by-count":103,"title":["Efficiency of CD19 chimeric antigen receptor-modified T cells for treatment of B cell malignancies in phase I clinical trials: a meta-analysis"],"prefix":"10.18632","volume":"6","author":[{"given":"Tengfei","family":"Zhang","sequence":"first","affiliation":[{"name":"Biotherapy Center, the First Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan, China"},{"name":"Department of Hematology and Oncology, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, Massachusetts, United States"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ling","family":"Cao","sequence":"additional","affiliation":[{"name":"Biotherapy Center, the First Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan, China"},{"name":"Department of Oncology, the First Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jing","family":"Xie","sequence":"additional","affiliation":[{"name":"Center for Eye Research Australia, Royal Victorian Eye and Ear Hospital, University of Melbourne, Melbourne, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ni","family":"Shi","sequence":"additional","affiliation":[{"name":"Comprehensive Cancer Center, the Ohio State University, Columbus, Ohio, United States"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhen","family":"Zhang","sequence":"additional","affiliation":[{"name":"Biotherapy Center, the First Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan, China"},{"name":"Department of Oncology, the First Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhenzhen","family":"Luo","sequence":"additional","affiliation":[{"name":"Biotherapy Center, the First Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan, China"},{"name":"Department of Oncology, the First Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dongli","family":"Yue","sequence":"additional","affiliation":[{"name":"Biotherapy Center, the First Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan, China"},{"name":"Department of Oncology, the First Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zimeng","family":"Zhang","sequence":"additional","affiliation":[{"name":"Department of Immunology, Harvard Medical School, Boston, Massachusetts United States"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liping","family":"Wang","sequence":"additional","affiliation":[{"name":"Department of Oncology, the First Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Weidong","family":"Han","sequence":"additional","affiliation":[{"name":"Molecular & Immunological\/Bio-Therapeutic Department, Institute of Basic Medicine, Chinese PLA General Hospital, Beijing, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhongwei","family":"Xu","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology, Pennsylvania Hospital, University of Pennsylvania, Philadelphia, Pennsylvania, United States"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hu","family":"Chen","sequence":"additional","affiliation":[{"name":"Department of Hematopoietic Stem Cell Transplantation, Affiliated Hospital to Academy of Military Medical Science, Beijing, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yi","family":"Zhang","sequence":"additional","affiliation":[{"name":"Biotherapy Center, the First Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan, China"},{"name":"Department of Oncology, the First Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan, China"},{"name":"Engineering Key Laboratory for Cell Therapy of Henan Province, Zhengzhou, Henan, China"},{"name":"School of Life Sciences, Zhengzhou University, Zhengzhou, Henan, China"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"7892","published-online":{"date-parts":[[2015,9,10]]},"reference":[{"key":"1","doi-asserted-by":"crossref","first-page":"2625","DOI":"10.1182\/blood-2013-11-492231","article-title":"Antibody-modified T cells: CARs take the front seat for hematologic malignancies","volume":"123","author":"June","year":"2014","journal-title":"Blood"},{"key":"2","doi-asserted-by":"crossref","first-page":"4129","DOI":"10.1182\/blood-2013-08-519413","article-title":"Donor-derived CD19-targeted T cells cause regression of malignancy persisting after allogeneic hematopoietic stem cell transplantation","volume":"122","author":"Gea-Banacloche","year":"2013","journal-title":"Blood"},{"key":"3","doi-asserted-by":"crossref","first-page":"2965","DOI":"10.1182\/blood-2013-06-506741","article-title":"Infusion of donor-derived CD19-redirected virus-specific T cells for B-cell malignancies relapsed after allogeneic stem cell transplant: a phase 1 study","volume":"122","author":"Kamble","year":"2013","journal-title":"Blood"},{"key":"4","doi-asserted-by":"crossref","first-page":"1509","DOI":"10.1056\/NEJMoa1215134","article-title":"Chimeric antigen receptor-modified T cells for acute lymphoid leukemia","volume":"368","author":"June","year":"2013","journal-title":"N Engl J Med"},{"key":"5","doi-asserted-by":"crossref","first-page":"725","DOI":"10.1056\/NEJMoa1103849","article-title":"Chimeric antigen receptor-modified T cells in chronic lymphoid leukemia","volume":"365","author":"June","year":"2011","journal-title":"N Engl J Med"},{"key":"6","first-page":"95ra73","article-title":"T cells with chimeric antigen receptors have potent antitumor effects and can establish memory in patients with advanced leukemia","volume":"3","author":"June","year":"2011","journal-title":"Sci Transl Med"},{"key":"7","doi-asserted-by":"crossref","first-page":"540","DOI":"10.1200\/JCO.2014.56.2025","article-title":"Chemotherapy-Refractory Diffuse Large B-Cell Lymphoma and Indolent B-Cell Malignancies Can Be Effectively Treated With Autologous T Cells Expressing an Anti-CD19 Chimeric Antigen Receptor","volume":"33","author":"Lu","year":"2015","journal-title":"J Clin Oncol"},{"key":"8","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1016\/S0140-6736(14)61403-3","article-title":"T cells expressing CD19 chimeric antigen receptors for acute lymphoblastic leukaemia in children and young adults: a phase 1 dose-escalation trial","volume":"385","author":"Tschernia","year":"2015","journal-title":"Lancet"},{"key":"9","doi-asserted-by":"crossref","first-page":"1245","DOI":"10.1016\/j.bbmt.2010.03.014","article-title":"Antitransgene rejection responses contribute to attenuated persistence of adoptively transferred CD20\/CD19-specific chimeric antigen receptor redirected T cells in humans","volume":"16","author":"Forman","year":"2010","journal-title":"Biol Blood Marrow Transplant"},{"key":"10","doi-asserted-by":"crossref","first-page":"4817","DOI":"10.1182\/blood-2011-04-348540","article-title":"Safety and persistence of adoptively transferred autologous CD19-targeted T cells in patients with relapsed or chemotherapy refractory B-cell leukemias","volume":"118","author":"Pegram","year":"2011","journal-title":"Blood"},{"key":"11","doi-asserted-by":"crossref","first-page":"2709","DOI":"10.1182\/blood-2011-10-384388","article-title":"B-cell depletion and remissions of malignancy along with cytokine-associated toxicity in a clinical trial of anti-CD19 chimeric-antigen-receptor-transduced T cells","volume":"119","author":"Devillier","year":"2012","journal-title":"Blood"},{"key":"12","doi-asserted-by":"crossref","first-page":"4099","DOI":"10.1182\/blood-2010-04-281931","article-title":"Eradication of B-lineage cells and regression of lymphoma in a patient treated with autologous T cells genetically engineered to recognize CD19","volume":"116","author":"Rosenberg","year":"2010","journal-title":"Blood"},{"key":"13","doi-asserted-by":"crossref","first-page":"1822","DOI":"10.1172\/JCI46110","article-title":"CD28 costimulation improves expansion and persistence of chimeric antigen receptor-modified T cells in lymphoma patients","volume":"121","author":"Rooney","year":"2011","journal-title":"J Clin Invest"},{"key":"14","doi-asserted-by":"crossref","first-page":"1507","DOI":"10.1056\/NEJMoa1407222","article-title":"Chimeric Antigen Receptor T Cells for Sustained Remissions in Leukemia","volume":"371","author":"Rheingold","year":"2014","journal-title":"New Engl J Med"},{"key":"15","first-page":"177ra38","article-title":"CD19-targeted T cells rapidly induce molecular remissions in adults with chemotherapy-refractory acute lymphoblastic leukemia","volume":"5","author":"Wasielewska","year":"2013","journal-title":"Sci Transl Med"},{"key":"16","doi-asserted-by":"crossref","first-page":"224ra25","DOI":"10.1126\/scitranslmed.3008226","article-title":"Efficacy and toxicity management of 19-28z CAR T cell therapy in B cell acute lymphoblastic leukemia","volume":"6","author":"He","year":"2014","journal-title":"Sci Transl Med"},{"key":"17","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1182\/blood.V71.1.13.13","article-title":"Detailed studies on expression and function of CD19 surface determinant by using B43 monoclonal antibody and the clinical potential of anti-CD19 immunotoxins","volume":"71","author":"Ledbetter","year":"1988","journal-title":"Blood"},{"key":"18","doi-asserted-by":"crossref","first-page":"255","DOI":"10.3109\/10428194.2012.715350","article-title":"Efficacy and safety of adoptive immunotherapy using anti-CD19 chimeric antigen receptor transduced T-cells: a systematic review of phase I clinical trials","volume":"54","author":"Tang","year":"2013","journal-title":"Leuk Lymphoma"},{"key":"19","doi-asserted-by":"crossref","first-page":"1077","DOI":"10.1182\/blood-2012-08-234492","article-title":"The myth of the second remission of acute leukemia in the adult","volume":"121","author":"Rowe","year":"2013","journal-title":"Blood"},{"key":"20","doi-asserted-by":"crossref","first-page":"3059","DOI":"10.1182\/blood-2014-06-583765","article-title":"Long-term results of first salvage treatment in CLL patients treated initially with FCR (fludarabine, cyclophosphamide, rituximab)","volume":"124","author":"Keating","year":"2014","journal-title":"Blood"},{"key":"21","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1016\/j.leukres.2013.10.004","article-title":"Dasatinib in combination with fludarabine in patients with refractory chronic lymphocytic leukemia: a multicenter phase 2 study","volume":"38","author":"van Oers","year":"2014","journal-title":"Leuk Res"},{"key":"22","doi-asserted-by":"crossref","first-page":"3836","DOI":"10.1182\/blood-2010-07-299321","article-title":"Definition and characterization of the systemic T-cell dysregulation in untreated indolent B-cell lymphoma and very early CLL","volume":"117","author":"Veelken","year":"2011","journal-title":"Blood"},{"key":"23","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1016\/j.hoc.2013.01.003","article-title":"Understanding the immunodeficiency in chronic lymphocytic leukemia: potential clinical implications","volume":"27","author":"Gribben","year":"2013","journal-title":"Hematol Oncol Clin North Am"},{"key":"24","doi-asserted-by":"crossref","first-page":"3367","DOI":"10.1182\/blood-2009-06-225326","article-title":"The microenvironment in mature B-cell malignancies: a target for new treatment strategies","volume":"114","author":"Caligaris-Cappio","year":"2009","journal-title":"Blood"},{"key":"25","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1182\/blood-2010-05-284984","article-title":"The lymph node microenvironment promotes B-cell receptor signaling, NF-kappaB activation, and tumor proliferation in chronic lymphocytic leukemia","volume":"117","author":"McCoy","year":"2011","journal-title":"Blood"},{"key":"26","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1182\/asheducation-2010.1.21","article-title":"Adolescents and young adults with acute lymphoblastic leukemia","volume":"2010","author":"Stock","year":"2010","journal-title":"Hematology Am Soc Hematol Educ Program"},{"key":"27","doi-asserted-by":"crossref","first-page":"432","DOI":"10.1038\/mt.2011.1","article-title":"CARs on track in the clinic","volume":"19","author":"Heslop","year":"2011","journal-title":"Mol Ther"},{"key":"28","doi-asserted-by":"crossref","first-page":"3831","DOI":"10.1182\/blood-2009-03-212134","article-title":"Harnessing the physiology of lymphopenia to support adoptive immunotherapy in lymphoreplete hosts","volume":"114","author":"Mackall","year":"2009","journal-title":"Blood"},{"key":"29","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1038\/nrc2355","article-title":"Adoptive cell transfer: a clinical path to effective cancer immunotherapy","volume":"8","author":"Dudley","year":"2008","journal-title":"Nat Rev Cancer"},{"key":"30","doi-asserted-by":"crossref","first-page":"388","DOI":"10.1158\/2159-8290.CD-12-0548","article-title":"The basic principles of chimeric antigen receptor design","volume":"3","author":"Rivi\u00e8re","year":"2013","journal-title":"Cancer Discov"},{"key":"31","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1172\/JCI0214941","article-title":"Activation and inhibition of lymphocytes by costimulation","volume":"109","author":"Thompson","year":"2002","journal-title":"J Clin Invest"},{"key":"32","doi-asserted-by":"crossref","first-page":"3131","DOI":"10.4049\/jimmunol.163.6.3131","article-title":"The role of the common cytokine receptor gamma-chain in regulating IL-2-dependent, activation-induced CD8+ T cell death","volume":"163","author":"Lakkis","year":"1999","journal-title":"J Immunol"},{"key":"33","doi-asserted-by":"crossref","first-page":"900","DOI":"10.4049\/jimmunol.173.2.900","article-title":"IL-21 enhances and sustains CD8+ T cell responses to achieve durable tumor immunity: comparative evaluation of IL-2, IL-15, and IL-21","volume":"173","author":"Shrikant","year":"2004","journal-title":"J Immunol"},{"key":"34","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1186\/1479-5876-8-104","article-title":"Comparison of anti-CD3 and anti-CD28-coated beads with soluble anti-CD3 for expanding human T cells: differing impact on CD8 T cell phenotype and responsiveness to restimulation","volume":"8","author":"Kurlander","year":"2010","journal-title":"J Transl Med"},{"key":"35","first-page":"235","article-title":"The inducible caspase-9 suicide gene system as a \u201csafety switch\u201d to limit on-target, off-tumor toxicities of chimeric antigen receptor T cells","volume":"5","author":"Brown","year":"2014","journal-title":"Front Pharmaco"},{"key":"36","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1038\/nbt.2459","article-title":"Combinatorial antigen recognition with balanced signaling promotes selective tumor eradication by engineered T cells","volume":"31","author":"Sadelain","year":"2013","journal-title":"Nat Biotechno"},{"key":"37","doi-asserted-by":"crossref","first-page":"2993","DOI":"10.1158\/1078-0432.CCR-14-2920","article-title":"CMVpp65 vaccine enhances the antitumor efficacy of adoptively transferred CD19-redirected CMV-specific T cells","volume":"21","author":"Zaia","year":"2015","journal-title":"Clin Cancer Res"},{"key":"38","doi-asserted-by":"crossref","first-page":"4133","DOI":"10.1182\/blood-2011-12-400044","article-title":"Tumor-targeted T cells modified to secrete IL-12 eradicate systemic tumors without need for prior conditioning","volume":"119","author":"Brentjens","year":"2012","journal-title":"Blood"},{"key":"39","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1038\/nri3405","article-title":"Molecular mechanisms of T cell co-stimulation and co-inhibition","volume":"13","author":"Flies","year":"2013","journal-title":"Nat Rev Immunol"},{"key":"40","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1038\/nrc3239","article-title":"The blockade of immune checkpoints in cancer immunotherapy","volume":"12","author":"Pardoll","year":"2012","journal-title":"Nat Rev Cancer"},{"key":"41","volume-title":"Cochrane handbook for systematic reviews of interventions","author":"Green","year":"2011","edition":"5"},{"key":"42","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1186\/2049-3258-72-39","article-title":"Metaprop: a Stata command to perform meta-analysis of binomial data","volume":"72","author":"Marc","year":"2014","journal-title":"Archives of Public Health"}],"container-title":["Oncotarget"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.oncotarget.com\/lookup\/doi\/10.18632\/oncotarget.5582","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,8,14]],"date-time":"2023-08-14T18:40:03Z","timestamp":1692038403000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.oncotarget.com\/lookup\/doi\/10.18632\/oncotarget.5582"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,9,10]]},"references-count":42,"journal-issue":{"issue":"32","published-print":{"date-parts":[[2015,10,20]]}},"alternative-id":["5582","26376680"],"URL":"https:\/\/doi.org\/10.18632\/oncotarget.5582","relation":{},"ISSN":["1949-2553"],"issn-type":[{"value":"1949-2553","type":"electronic"}],"subject":[],"published":{"date-parts":[[2015,9,10]]}}}